Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
Life on Ocrevus
OCREVUS SC Practical Guides
Patient Resources
OCREVUS SC: Real-World Experiences
OCREVUS Data
Contact Us
Life on OCREVUS: Real stories from people with MS
Life on Ocrevus
OCREVUS SC Practical Guides
Patient Resources
OCREVUS SC: Real-World Experiences
OCREVUS Data
Contact Us
OCREVUS SC Practical Guides
Discover essential data and information on OCREVUS SC to support your formulary applications.
A checklist that aims to support HCPs with the administration of OCREVUS SC.
Find instructions on how to prepare and administer OCREVUS SC in the injection pack.
Support with your administration and storage protocol for OCREVUS SC.
A video guide providing a clear, step-by-step demonstration of the preparation and administration injection process of OCREVUS SC.
Patient Resources
The following sections contain resources to support patients who have been prescribed OCREVUS.
Ocrevus
Neuroscience
Explore a variety of materials to support patients in their journey on OCREVUS.
Clicking this link will take you to an external website with information and support for patients who have been prescribed OCREVUS.
OCREVUS SC: Real-World Experiences
These videos offer the multidisciplinary team (MDT) perspective on the implementation process and the impact of introducing OCREVUS SC for people with MS.
This series of videos features members of the MS MDT based at Newcastle Hospitals NHS Foundation Trust discussing their experience of implementing OCREVUS SC at the MS Trust symposium in March 2025.
OCREVUS Data
Access information on treatment strategies with OCREVUS in the context of family planning and breastfeeding, in line with the new label update.
This video offers an overview of the OCARINA | and OCARINA II clinical trials and explores the SC formulation by Consultant Neurologist, Dr. Martin Duddy.
Contact Us
References:
- OCREVUS IV Summary of Product Characteristics
2. OCREVUS SC Summary of Product Characteristics
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.
